NCT03565029CompletedPhase 2
Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer
Total Neoadjuvant Treatment Without Surgery For Locally Advanced Rectal Cancer: Prospective Clinical Trial To Assess Tumor Complete Response, Circulating Tumor Genetic And Epigenetic Biomarkers, And Stromal Transcriptome To Interpret Clinical Outcome
Source: ClinicalTrials.gov · Last updated 27 Dec 2024
Brief summary (registry, in English)
NO-CUT is a one-stage phase II trial seeking to establish whether an oxaliplatin-based chemotherapy preceding standard neo-adjuvant fluoropyrimidines-based chemo radiotherapy, can safely spare demolitive surgical intervention in patients with operable rectal cancer, without increasing the risk of distant relapse. The trial also has a translational component aimed at establishing whether selected genomic, epigenetic, and transcriptomic markers are predictive of tumor and patient outcome.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 180 (actual)
- First submitted
- 8 Jun 2018
- Start date
- 1 Jun 2018
- Primary completion date
- 31 Oct 2022
- Lead sponsor
- Niguarda Hospital
- Diseases
- Colorectal cancer
- NCT number
- NCT03565029
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 180
- From 1 Jun 2018 to the primary completion date, 31 Oct 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with any other concurrent medical or psychiatric condition
- Patients with a history of thrombotic episodes, such as deep venous thrombosis, pulmonary embolus, Myocardial Infarction (MI) or cerebral vascular accident (CVA) occurring more than 6 months prior to enrollment may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Patients who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy.
- Patients receiving other anticancer or experimental therapy.
Other illness
- Recurrent rectal cancer
- Patients with a history of any arterial thrombotic event within the past 6 months, including angina (stable or unstable), MI, or CVA
- Gastro-intestinal abnormalities, inability to take oral medication, any condition affecting absorption
- Patients with a history of a prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
Other
- Intolerance or contraindication to Magnetic Resonance (MR) procedure
Who the study is looking for
- Histologically confirmed diagnosis of adenocarcinoma of the medium/lower rectum
- Patients must have Stage II (cT3-4 N0) or Stage III (cT1-4, N1-3) tumor
- Locally advanced rectal cancer amenable to Total Mesorectal Excision (TME)/Abdominal-Perineal Amputation
- No evidence of distant metastases by chest, abdomen, and pelvis contrast enhanced CT scan (TC-positron emission computed tomography (PET) Whole Body (WB) is acceptable alternative in patient allergic to iodate contrast medium)
- No prior pelvic radiation therapy
- No prior oncologic medical therapy or surgery for rectal cancer
- Age \>18 years
- No infections requiring systemic antibiotic treatment
- Performance status 0-1 (ECOG Scale)
- absolute neutrophil count (ANC) \> 1.5 cell/mm3, Hb\>8.0 g/ dL, Platelet Count (PLT)\>150,000/mm3, total bilirubin \< or equal or 1.5 x upper limit of normal, Aspartate Aminotransferase (AST) \< or equal to three times upper limit of normal, Alanine Aminotransferase (ALT)\< or equal to three times upper limit of normal; Serum creatinine level \< or equal to 1.5 times the upper limit of normal
- Patients must read, agree to, and sign a statement of Informed Consent prior to participation
- Women with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use effective contraceptive methods
- Male subjects must also agree to use effective contraception
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST GOM Niguarda Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.